Drug intelligence / Profile preview

Hedan

Development stage: Unknown
Lead developer: Shandong Wohua Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Hedan is a traditional Chinese medicine (TCM) herbal formulation developed and marketed by Shandong Wohua Pharmaceutical for the treatment of metabolic and lipid disorders. Available in both tablet (Hedan Pian) and capsule (Hedan Jiaonang) forms, it is also indicated for cardiovascular and cerebrovascular diseases. As a multi-herb TCM product, its therapeutic effect is derived from the synergistic action of its constituent botanical ingredients, which are traditionally used to regulate lipids and improve circulation. It is a core product in the developer's cardio-cerebral vascular medicine portfolio and has received regulatory approval in China.

Brand names: HedanHedan PianHedan Jiaonang
Other names: 荷丹片荷丹胶囊

Targets

PPARA (Peroxisome proliferator-activated receptor alpha)IL-6 (Interleukin 6)

Beyond the preview

Go deeper on Hedan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hedan.

Explore the full profile